查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球癌症生物標記市場：按分析技術、按癌症類型、按產品、按應用、按最終用戶、按地區 - 預測至 2029 年
市場調查報告書
商品編碼
1473750

全球癌症生物標記市場：按分析技術、按癌症類型、按產品、按應用、按最終用戶、按地區 - 預測至 2029 年

Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), Enduser, and Region - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 339 Pages | 訂單完成後即時交付

價格
簡介目錄

全球癌症生物標記市場規模預計將從 2024 年的 245 億美元增至 2029 年的 420 億美元，預測期內複合年成長率為 11.3%。

癌症生物標記創建技術的快速進步以及全球癌症發病率上升等因素正在推動市場擴張。然而，這一市場擴張的主要障礙是檢驗癌症生物標記的困難和缺乏合格的人員。

調查範圍
調查年份 2022-2029
基準年 2023年
預測期 2024-2029
考慮單位 金額（十億美元）
部分 依分析技術、癌症類型、產品、應用、最終用戶、區域
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東/非洲、海灣合作理事會國家

根據分析方法，癌症生物標記市場分為兩個部分：體學技術和成像技術。體學技術在 2023 年的年複合成長率（CAGR）最高。這是因為蛋白質體學和基因組學擴大被用於改善藥物開發、藥物發現和癌症診斷。

在2023年的癌症生物標記市場中，乳癌類別呈現最快的成長速度。技術進步全球癌症盛行率的增加和癌症生物標記的開拓是推動該領域成長的兩個關鍵方面。

依應用來看，研發領域2020年複合年成長率最高。這是由於癌症生物標記研究和開發的增加以及癌症生物標記在藥物發現和開發中的應用不斷擴大。

從最終用戶來看，到 2023 年，診斷實驗室領域將在癌症生物標記市場中佔據更大佔有率。全球範圍內進行基於癌症生物標記的診斷測試的臨床實驗室數量的增加以及惡性患病率的上升正在推動這一最終用戶領域佔據很大的佔有率。

該報告考察了全球癌症生物標記市場，並按技術、癌症類型、產品、應用、最終用戶、地區和進入市場的公司概況總結了趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 介紹
  • 市場動態
  • 價格分析
  • 專利分析
  • 價值鏈分析
  • 供應鏈分析
  • 癌症生物標記市場生態系統分析
  • 波特五力分析
  • 監管分析
  • 貿易分析
  • 診斷檢測試劑貿易分析
  • 技術分析
  • 主要技術
  • 互補技術
  • 鄰近技術
  • 2024-2025年重大會議和活動
  • 影響客戶業務的趨勢/干擾
  • 主要相關人員和採購標準
  • 案例研究分析
  • 投資金籌措場景

第6章癌症生物標記市場（按分析技術）

  • 介紹
  • 體學技術
  • 成像技術

第7章癌症生物標記市場（按癌症類型）

  • 介紹
  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 黑色素瘤
  • 白血病
  • 甲狀腺癌
  • 膀胱癌
  • 非何傑金氏淋巴瘤
  • 腎癌
  • 其他

第8章癌症生物標記市場，副產品

  • 介紹
  • 裝置
  • 消耗品
  • 生物資訊軟體

第9章癌症生物標記市場，依應用分類

  • 介紹
  • 診斷
  • 研究與開發
  • 預後
  • 風險評估
  • 其他

第 10 章癌症生物標記市場（按最終用戶）

  • 介紹
  • 診斷實驗室
  • 生物製藥公司和 CRO
  • 研究/學術機構
  • 其他

第11章癌症生物標記市場，按地區

  • 介紹
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲
  • 海灣合作理事會國家

第12章競爭格局

  • 概述
  • 主要參與企業所採取的秘密策略
  • 收益佔有率分析
  • 市場佔有率分析
  • 企業評價矩陣：主要參與企業
  • 競爭評估矩陣：Start-Ups/小型企業 (2023)
  • 癌症生物標記供應商評估和財務指標
  • 品牌/產品比較分析
  • 競爭場景

第13章 公司簡介

  • 主要參與企業
    • F. HOFFMANN-LA ROCHE LTD.
    • THERMO FISHER SCIENTIFIC INC.
    • QIAGEN
    • BIO-RAD LABORATORIES, INC.
    • ILLUMINA, INC.
    • AGILENT TECHNOLOGIES, INC.
    • ABBOTT LABORATORIES
    • BIOMERIEUX
    • MERCK KGAA
    • BECTON, DICKINSON AND COMPANY
  • 其他公司
    • MYRIAD GENETICS, INC.
    • SYSMEX CORPORATION
    • HOLOGIC, INC.
    • QUEST DIAGNOSTICS
    • CENTOGENE NV
    • BIOGENEX
    • SIEMENS HEALTHINEERS
    • EXACT SCIENCES
    • R&D SYSTEMS, INC.
    • BIOVISION INC.
    • OLINK
    • ASURAGEN, INC.
    • MESO SCALE DIAGNOSTICS, LLC
    • INVIVOSCRIBE, INC.
    • INOVIQ LTD.

第14章附錄

簡介目錄
Product Code: MD 5627

The global cancer biomarkers market is projected to reach USD 42.0 billion by 2029 from USD 24.5 billion in 2024, at a CAGR of 11.3% during the forecast period. Factors like the rapid improvements in technology propel market expansion. in the creation of cancer biomarkers and the global rise in cancer incidence. However, the main obstacles to this market's expansion are the difficulties in validating cancer biomarkers and the lack of qualified workers.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsProfiling technology, cancer type, product type, application, end-user, and region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries

"Omics technologies segment accounted for the highest CAGR"

The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. Omics technology had the highest compound annual growth rate (CAGR) in 2023. This is explained by the growing use of proteomics and genomics in medication development and discovery as well as improved cancer diagnostics.

"The breast cancer segment accounted for the highest growth rate in the cancer biomarkers market, by cancer type, during the forecast period"

The market for cancer biomarkers is divided into categories according on the kind of cancer, including non-Hodgkin's lymphoma, kidney cancer, bladder cancer, thyroid cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, and other cancer types. In the market for cancer biomarkers in 2023, the breast cancer category had the fastest growth rate. increasing progress in technology The increasing global prevalence of cancer and the development of cancer biomarkers are two important aspects driving this segment's growth.

"Diagnostics segment accounted for the highest share"

The market for cancer biomarkers has been divided into segments based on application, including risk assessment, prognostics, diagnostics, and research & development. 2020 had the highest CAGR in the research and development sector. This can be linked to the rise in cancer biomarker research and development as well as the growing application of cancer biomarkers in medication discovery and development.

"Diagnostic Laboratories segment accounted for the highest share"

Based on end user, the cancer biomarker market is segmented into diagnostic laboratories, Biopharmaceutical Companies & CROs, research and academic institutes and other end-users. In 2023, the diagnostic laboratories segment accounted for a larger share of the cancer biomarkers market. he expanding number of clinical laboratories performing cancer biomarker-based diagnostics tests worldwide and the rising prevalence of malignancies are responsible for this end-user segment's sizeable share.

"Asia Pacific: The fastest-growing region in cancer biomarkers market"

The global cancer biomarkers market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Rising technological advancements In the development of cancer biomarkers and increasing incidence of cancer worldwide are driving the growth of the cancer biomarkers market in this region.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
  • By Designation: C-level (27%), Director-level (18%), and Others (55%)
  • By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)

Lists of Companies Profiled in the Cancer Biomarkers Market Report:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Thermo Fisher Scientific, Inc. (US)
  • QIAGEN N.V. (Netherlands)
  • Illumina, Inc. (US)
  • Bio-Rad Laboratories, Inc. (US)
  • Abbott Laboratories (US)
  • bioMerieux SA (US)
  • Becton, Dickinson and Company (US)
  • Merck Millipore (US)
  • Agilent Technologies (US)
  • Myriad Genetics, Inc. (US)
  • Sysmex Corporation (Japan)
  • Hologic, Inc. (US)
  • Quest Diagnostics (US)
  • Centogene N.V. (Germany)
  • BioGenex (India),
  • Siemens Healthineers (Germany)
  • Exact Sciences (US)
  • R&D Systems, Inc. (US)
  • BioVision, Inc. (US)
  • Olink (Sweden)
  • Asuragen, Inc. (US)
  • Meso Scale Diagnostics, LLC (US)
  • Invivoscribe, Inc. (US)
  • INOVIQ Ltd. (Australia)

Research Coverage

This research report categorizes the cancer biomarker market by profiling technology, cancer type, product type, application, enduser, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the optometry equipment market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the Surface disinfectant market. Competitive analysis of upcoming startups in the optometry equipment market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cancer biomarker market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (High prevalence of cancer, growing use for research and diagnosis), restraints (Technical issues related to sample collection and storage), opportunities (Rising healthcare expenditure, Increasing Demand from Emerging Economies), and challenges (lack of skilled professionals) influencing the growth of the cancer biomarker market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the cancer biomarker market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the cancer biomarker market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer biomarker market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), among others in cancer biomarker market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • TABLE 1 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION
    • FIGURE 2 REGIONAL SCOPE
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
    • 1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 3 CANCER BIOMARKERS MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 8 CANCER BIOMARKERS MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
    • 2.7.1 RISK ASSESSMENT: CANCER BIOMARKERS MARKET
  • 2.8 GROWTH RATE ASSUMPTIONS
  • 2.9 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 10 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    • FIGURE 11 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 12 CANCER BIOMARKERS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
    • FIGURE 13 CANCER BIOMARKERS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 14 CANCER BIOMARKERS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 15 CANCER BIOMARKERS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 CANCER BIOMARKERS MARKET OVERVIEW
    • FIGURE 16 TECHNOLOGICAL ADVANCEMENTS IN CANCER BIOMARKERS TO DRIVE MARKET
  • 4.2 CANCER BIOMARKERS MARKET SHARE, BY PROFILING TECHNOLOGY, 2024 VS. 2029
    • FIGURE 17 OMICS TECHNOLOGIES TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2024 VS. 2029
    • FIGURE 18 LUNG CANCER SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2029
  • 4.4 CANCER BIOMARKERS MARKET SHARE, BY PRODUCT, 2024 VS. 2029
    • FIGURE 19 INSTRUMENTS SEGMENT TO DOMINATE CANCER BIOMARKERS MARKET IN 2024
  • 4.5 CANCER BIOMARKERS MARKET SHARE, BY APPLICATION, 2024 VS. 2029
    • FIGURE 20 DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2029
  • 4.6 CANCER BIOMARKERS MARKET SHARE, BY END USER, 2024 VS. 2029
    • FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.7 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 23 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Technological advancements in cancer biomarkers
      • 5.2.1.2 Increasing incidence of cancer
    • TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
    • TABLE 3 PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2015-2035
      • 5.2.1.3 Rising use of cancer biomarkers in drug discovery & development
      • 5.2.1.4 Increasing R&D on cancer biomarkers
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Technical issues related to sample collection and storage
      • 5.2.2.2 High capital investments and extensive timelines for development of cancer biomarkers
    • TABLE 4 TIMEFRAME FOR DEVELOPMENT OF BIOMARKERS
      • 5.2.2.3 Unfavorable regulatory and reimbursement scenarios
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Personalized medicine
    • FIGURE 24 WORKFLOW FOR PERSONALIZED TREATMENT
    • FIGURE 25 PERCENTAGE OF CANCER CLINICAL TRIALS INCORPORATING CANCER BIOMARKERS
      • 5.2.3.2 Growing applications of companion diagnostics
    • TABLE 5 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS
      • 5.2.3.3 Emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Challenges associated with cancer biomarker validation
      • 5.2.4.2 Shortage of skilled professionals
  • 5.3 PRICING ANALYSIS
    • 5.3.1 PRICING MODEL ANALYSIS
    • TABLE 6 INDICATIVE PRICING FOR CANCER BIOMARKER PRODUCTS (2023)
    • TABLE 7 AVERAGE SELLING PRICE OF CANCER BIOMARKER PRODUCTS, BY REGION
  • 5.4 PATENT ANALYSIS
    • 5.4.1 PATENT ANALYSIS OF CANCER BIOMARKERS MARKET
    • FIGURE 26 PATENT ANALYSIS FOR CANCER BIOMARKERS (JANUARY 2014-DECEMBER 2023)
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 27 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 28 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS OF CANCER BIOMARKERS MARKET
    • FIGURE 29 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
    • 5.7.1 ROLE IN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 8 CANCER BIOMARKERS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 INTRODUCTION
    • 5.9.2 CANCER BIOMARKERS QUALIFICATION IN US
    • 5.9.3 CANCER BIOMARKERS QUALIFICATION IN EU
    • FIGURE 30 CANCER BIOMARKERS MARKET: EMA QUALIFICATION PROCEDURE
    • 5.9.4 CANCER BIOMARKERS ACCEPTANCE IN DRUG DEVELOPMENT IN EU AND US
    • 5.9.5 EMA APPROVALS
    • 5.9.6 FDA APPROVALS
  • 5.10 TRADE ANALYSIS
  • 5.11 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
    • TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.12 TECHNOLOGY ANALYSIS
  • 5.13 KEY TECHNOLOGIES
    • 5.13.1 POLYMERASE CHAIN REACTION
    • 5.13.2 NEXT-GENERATION SEQUENCING
  • 5.14 COMPLEMENTARY TECHNOLOGIES
    • 5.14.1 IN SITU HYBRIDIZATION
  • 5.15 ADJACENT TECHNOLOGIES
    • 5.15.1 IMMUNOHISTOCHEMISTRY
  • 5.16 KEY CONFERENCES & EVENTS IN 2024-2025
    • TABLE 11 CANCER BIOMARKERS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
    • 5.17.1 REVENUE SHIFT & REVENUE POCKETS FOR CANCER BIOMARKERS MARKET
    • FIGURE 31 REVENUE SHIFT FOR CANCER BIOMARKERS MARKET
  • 5.18 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.18.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS
    • TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS
    • 5.18.2 BUYING CRITERIA
    • FIGURE 33 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS
    • TABLE 13 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS
  • 5.19 CASE STUDY ANALYSIS
    • 5.19.1 CASE STUDY: CASE OF OVARIAN CANCER TO ILLUSTRATE BEST PRACTICE IN MACHINE LEARNING AND SHAPLEY ANALYSIS
  • 5.20 INVESTMENT & FUNDING SCENARIO
    • TABLE 14 US: CANCER BIOMARKERS FUNDING BY VARIOUS INSTITUTES/CENTERS, 2021-2024

6 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY

  • 6.1 INTRODUCTION
    • TABLE 15 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
  • 6.2 OMICS TECHNOLOGIES
    • TABLE 16 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 17 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
    • 6.2.1 PROTEOMICS
    • TABLE 18 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 19 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2022-2029 (USD MILLION)
      • 6.2.1.1 Immunoassays
        • 6.2.1.1.1 Facilitate diagnosis of cancer at early stage
    • TABLE 20 IMMUNOASSAYS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 6.2.1.2 Mass spectrometry
        • 6.2.1.2.1 High specificity of mass spectroscopy to drive adoption
    • TABLE 21 MASS SPECTROMETRY MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 6.2.1.3 2D gel electrophoresis
        • 6.2.1.3.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive segment
    • TABLE 22 2D GEL ELECTROPHORESIS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 6.2.1.4 Protein microarrays
        • 6.2.1.4.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive growth
    • TABLE 23 PROTEIN MICROARRAYS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 6.2.1.5 Other proteomic technologies
    • TABLE 24 OTHER PROTEOMIC TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.2.2 GENOMICS
    • TABLE 25 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 26 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2022-2029 (USD MILLION)
      • 6.2.2.1 Next-generation sequencing
        • 6.2.2.1.1 Development of advanced NGS platforms by leading players to drive growth
    • TABLE 27 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 6.2.2.2 Polymerase chain reaction
        • 6.2.2.2.1 Cost-effectiveness and easy availability of PCR tests to propel market
    • TABLE 28 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 6.2.2.3 In situ hybridization
        • 6.2.2.3.1 ISH-based diagnostic tests help identify specific biomarkers in clinical trials
    • TABLE 29 IN SITU HYBRIDIZATION MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.2.3 OTHER OMICS TECHNOLOGIES
    • TABLE 30 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
  • 6.3 IMAGING TECHNOLOGIES
    • TABLE 31 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 32 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
    • 6.3.1 ULTRASOUND IMAGING
      • 6.3.1.1 Use of ultrasound for biomarker research in understanding disease onset & progression to drive growth
    • TABLE 33 ULTRASOUND IMAGING MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.3.2 COMPUTED TOMOGRAPHY
      • 6.3.2.1 Technological advancements to drive adoption
    • TABLE 34 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.3.3 MAGNETIC RESONANCE IMAGING
      • 6.3.3.1 Growing preference for open MRIs to support market growth
    • TABLE 35 MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.3.4 POSITRON EMISSION TOMOGRAPHY
      • 6.3.4.1 Development of lab-on-chip-based multiplex assays to propel market
    • TABLE 36 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 6.3.5 MAMMOGRAPHY
      • 6.3.5.1 Advanced technologies like 3D mammography to support market growth
    • TABLE 37 MAMMOGRAPHY MARKET, BY REGION, 2022-2029 (USD MILLION)

7 CANCER BIOMARKERS MARKET, BY CANCER TYPE

  • 7.1 INTRODUCTION
    • TABLE 38 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 39 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040
  • 7.2 BREAST CANCER
    • 7.2.1 INCREASING PREVALENCE OF BREAST CANCER TO DRIVE MARKET
    • TABLE 40 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040
    • TABLE 41 CANCER BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2022-2029 (USD MILLION)
  • 7.3 LUNG CANCER
    • 7.3.1 INCREASING FOCUS ON DEVELOPMENT OF LUNG CANCER BIOMARKERS TO SUPPORT MARKET GROWTH
    • TABLE 42 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040
    • TABLE 43 CANCER BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2022-2029 (USD MILLION)
  • 7.4 COLORECTAL CANCER
    • 7.4.1 RISING DEMAND FOR BIOMARKERS IN EARLY DIAGNOSIS & PROGNOSIS OF COLORECTAL CANCER TO DRIVE MARKET
    • TABLE 44 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040
    • TABLE 45 CANCER BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2029 (USD MILLION)
  • 7.5 PROSTATE CANCER
    • 7.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES TO PROPEL MARKET
    • TABLE 46 CANCER BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2022-2029 (USD MILLION)
  • 7.6 MELANOMA
    • 7.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE MARKET
    • TABLE 47 ESTIMATED NUMBER OF MELANOMA CASES, BY REGION, 2022 VS. 2040
    • TABLE 48 CANCER BIOMARKERS MARKET FOR MELANOMA, BY REGION, 2022-2029 (USD MILLION)
  • 7.7 LEUKEMIA
    • 7.7.1 INCREASING NUMBER OF RESEARCH STUDIES FOR DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS FOR LEUKEMIA TO DRIVE MARKET
    • TABLE 49 CANCER BIOMARKERS MARKET FOR LEUKEMIA, BY REGION, 2022-2029 (USD MILLION)
  • 7.8 THYROID CANCER
    • 7.8.1 INCREASING RESEARCH FOR IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO SUPPORT MARKET GROWTH
    • TABLE 50 CANCER BIOMARKERS MARKET FOR THYROID CANCER, BY REGION, 2022-2029 (USD MILLION)
  • 7.9 BLADDER CANCER
    • 7.9.1 INCREASING APPROVALS OF URINARY BIOMARKERS FOR DETECTION OF BLADDER CANCER TO PROPEL MARKET
    • TABLE 51 CANCER BIOMARKERS MARKET FOR BLADDER CANCER, BY REGION, 2022-2029 (USD MILLION)
  • 7.10 NON-HODGKIN'S LYMPHOMA
    • 7.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE MARKET
    • TABLE 52 CANCER BIOMARKERS MARKET FOR NON-HODGKIN'S LYMPHOMA, BY REGION, 2022-2029 (USD MILLION)
  • 7.11 KIDNEY CANCER
    • 7.11.1 DEVELOPMENT OF NEW TARGETED THERAPIES FOR TREATMENT OF KIDNEY CANCER TO DRIVE MARKET
    • TABLE 53 CANCER BIOMARKERS MARKET FOR KIDNEY CANCER, BY REGION, 2022-2029 (USD MILLION)
  • 7.12 OTHER CANCERS
    • TABLE 54 CANCER BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2022-2029 (USD MILLION)

8 CANCER BIOMARKERS MARKET, BY PRODUCT

  • 8.1 INTRODUCTION
    • TABLE 55 CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • 8.2 INSTRUMENTS
    • TABLE 56 CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 57 CANCER BIOMARKER INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 8.2.1 IMAGING INSTRUMENTS
      • 8.2.1.1 Technological advancements in imaging instruments to drive growth
    • TABLE 58 IMAGING INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 8.2.2 PATHOLOGY-BASED INSTRUMENTS
      • 8.2.2.1 Rising demand for cancer diagnosis to drive market
    • TABLE 59 PATHOLOGY-BASED INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 8.2.3 BIOPSY INSTRUMENTS
      • 8.2.3.1 Increasing prevalence of cancer to drive growth
    • TABLE 60 BIOPSY INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 8.3 CONSUMABLES
    • TABLE 61 CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 62 CANCER BIOMARKER CONSUMABLES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 8.3.1 ANTIBODIES
      • 8.3.1.1 Increasing approvals for therapeutic antibodies by regulatory authorities to drive market
    • TABLE 63 ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 8.3.2 KITS & REAGENTS
      • 8.3.2.1 Ease of use to support adoption
    • TABLE 64 KITS & REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 8.3.3 PROBES
      • 8.3.3.1 Need for probes in assay tests for cancer detection to support market growth
    • TABLE 65 PROBES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 8.4 BIOINFORMATICS SOFTWARE
    • 8.4.1 TECHNOLOGICAL ADVANCEMENTS AND GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET
    • TABLE 66 CANCER BIOMARKER BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2022-2029 (USD MILLION)

9 CANCER BIOMARKERS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 67 CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • 9.2 DIAGNOSTICS
    • 9.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO PROPEL MARKET
    • TABLE 68 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • 9.3 RESEARCH & DEVELOPMENT
    • 9.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON USE OF BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
    • TABLE 69 CANCER BIOMARKERS MARKET FOR RESEARCH & DEVELOPMENT APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • 9.4 PROGNOSTICS
    • 9.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO SUPPORT MARKET GROWTH
    • TABLE 70 CANCER BIOMARKERS MARKET FOR PROGNOSTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • 9.5 RISK ASSESSMENT
    • 9.5.1 USED FOR DETECTING MUTATIONS OR VARIANTS IN GERMLINE DNA OF INDIVIDUALS
    • TABLE 71 CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • 9.6 OTHER APPLICATIONS
    • TABLE 72 CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)

10 CANCER BIOMARKERS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 73 CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.2 DIAGNOSTIC LABORATORIES
    • 10.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH
    • TABLE 74 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • 10.3 BIOPHARMACEUTICAL COMPANIES AND CROS
    • 10.3.1 RISING FOCUS ON DRUG DISCOVERY IN BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
    • TABLE 75 CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2022-2029 (USD MILLION)
  • 10.4 RESEARCH AND ACADEMIC INSTITUTES
    • 10.4.1 INCREASING RESEARCH FUNDING FOR EARLY DIAGNOSIS TO AUGMENT MARKET
    • TABLE 76 CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • 10.5 OTHER END USERS
    • TABLE 77 CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)

11 CANCER BIOMARKERS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 78 CANCER BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 11.2 NORTH AMERICA
    • TABLE 79 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2022
    • FIGURE 34 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT
    • TABLE 80 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 81 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 82 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 83 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 84 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 85 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 86 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 87 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 88 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 89 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 90 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 91 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.2.1 NORTH AMERICA: RECESSION IMPACT
    • 11.2.2 US
      • 11.2.2.1 Increasing use of cancer biomarkers for cancer treatment to drive market
    • TABLE 92 KEY GROWTH STRATEGIES BY LEADING PLAYERS FOR DEVELOPMENT OF CANCER BIOMARKERS
    • TABLE 93 US: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
    • TABLE 94 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 95 US: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 96 US: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 97 US: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 98 US: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 99 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 100 US: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 101 US: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 102 US: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 103 US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 104 US: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.2.3 CANADA
      • 11.2.3.1 Increasing government initiatives for discovery and development of cancer biomarkers to drive growth
    • TABLE 105 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
    • TABLE 106 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 107 CANADA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 108 CANADA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 109 CANADA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 110 CANADA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 111 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 112 CANADA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 113 CANADA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 114 CANADA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 115 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 116 CANADA: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 117 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 118 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 119 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 120 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 121 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 122 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 123 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 124 EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 125 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 126 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 127 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 128 EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.1 EUROPE: RECESSION IMPACT
    • 11.3.2 GERMANY
      • 11.3.2.1 Favorable government health policies to drive market
    • TABLE 129 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 130 GERMANY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 131 GERMANY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 132 GERMANY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 133 GERMANY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 134 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 135 GERMANY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 136 GERMANY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 137 GERMANY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 138 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 139 GERMANY: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.3 UK
      • 11.3.3.1 Availability of government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
    • TABLE 140 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 141 UK: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 142 UK: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 143 UK: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 144 UK: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 145 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 146 UK: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 147 UK: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 148 UK: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 149 UK: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 150 UK: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.4 FRANCE
      • 11.3.4.1 Increasing government investments in genomics & proteomics research to drive market
    • TABLE 151 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 152 FRANCE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 153 FRANCE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 154 FRANCE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 155 FRANCE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 156 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 157 FRANCE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 158 FRANCE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 159 FRANCE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 160 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 161 FRANCE: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.5 ITALY
      • 11.3.5.1 Growing geriatric population to support market growth
    • TABLE 162 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 163 ITALY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 164 ITALY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 165 ITALY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 166 ITALY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 167 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 168 ITALY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 169 ITALY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 170 ITALY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 171 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 172 ITALY: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.6 SPAIN
      • 11.3.6.1 Increasing focus on personalized medicine to propel market
    • TABLE 173 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 174 SPAIN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 175 SPAIN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 176 SPAIN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 177 SPAIN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 178 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 179 SPAIN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 180 SPAIN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 181 SPAIN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 182 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 183 SPAIN: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 184 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 185 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 186 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 187 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 188 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 189 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 190 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 191 REST OF EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 192 REST OF EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 193 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 194 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 35 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT
    • TABLE 195 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 196 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 197 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 198 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 199 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 200 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 201 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 202 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 203 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 204 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 205 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 206 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 11.4.2 CHINA
      • 11.4.2.1 Advancements in healthcare facilities to drive market
    • TABLE 207 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
    • TABLE 208 CHINA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 209 CHINA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 210 CHINA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 211 CHINA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 212 CHINA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 213 CHINA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 214 CHINA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 215 CHINA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 216 CHINA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 217 CHINA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 218 CHINA: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.3 JAPAN
      • 11.4.3.1 Research initiatives to support market growth
    • TABLE 219 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
    • TABLE 220 JAPAN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 221 JAPAN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 222 JAPAN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 223 JAPAN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 224 JAPAN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 225 JAPAN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 226 JAPAN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 227 JAPAN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 228 JAPAN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 229 JAPAN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 230 JAPAN: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.4 INDIA
      • 11.4.4.1 Increased demand for early cancer diagnosis to drive market
    • TABLE 231 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
    • TABLE 232 INDIA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 233 INDIA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 234 INDIA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 235 INDIA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 236 INDIA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 237 INDIA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 238 INDIA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 239 INDIA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 240 INDIA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 241 INDIA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 242 INDIA: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.5 REST OF ASIA PACIFIC
    • TABLE 243 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 244 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 245 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 246 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 247 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 248 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 249 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 250 REST OF ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 251 REST OF ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 252 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 253 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.5 LATIN AMERICA
    • TABLE 254 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 255 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 256 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 257 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 258 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 259 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 260 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 261 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 262 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 263 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 264 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 265 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.5.1 LATIN AMERICA: RECESSION IMPACT
    • 11.5.2 BRAZIL
      • 11.5.2.1 Increasing incidence of cancer to drive market
    • TABLE 266 BRAZIL: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 267 BRAZIL: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 268 BRAZIL: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 269 BRAZIL: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 270 BRAZIL: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 271 BRAZIL: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 272 BRAZIL: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 273 BRAZIL: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 274 BRAZIL: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 275 BRAZIL: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 276 BRAZIL: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.5.3 MEXICO
      • 11.5.3.1 Growing medical tourism to fuel demand for cancer diagnostics
    • TABLE 277 MEXICO: NUMBER OF CANCER CASES, BY CANCER TYPE, 2022
    • TABLE 278 MEXICO: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 279 MEXICO: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 280 MEXICO: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 281 MEXICO: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 282 MEXICO: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 283 MEXICO: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 284 MEXICO: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 285 MEXICO: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 286 MEXICO: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 287 MEXICO: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 288 MEXICO: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.5.4 REST OF LATIN AMERICA
    • TABLE 289 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 290 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 291 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 292 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 293 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 294 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 295 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 296 REST OF LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 297 REST OF LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 298 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 299 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET
    • TABLE 300 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 301 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 302 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 303 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 304 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 305 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 306 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 307 MIDDLE EAST & AFRICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 308 MIDDLE EAST & AFRICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 309 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 310 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
  • 11.7 GCC
    • 11.7.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
    • TABLE 311 GCC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 312 GCC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 313 GCC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 314 GCC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 315 GCC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 316 GCC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022-2029 (USD MILLION)
    • TABLE 317 GCC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 318 GCC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 319 GCC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 320 GCC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 321 GCC: CANCER BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.7.2 GCC: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER BIOMARKERS MARKET
    • TABLE 322 CANCER BIOMARKERS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 12.3 REVENUE SHARE ANALYSIS
    • FIGURE 36 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2019-2023 (USD MILLION)
  • 12.4 MARKET SHARE ANALYSIS
    • FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
    • TABLE 323 CANCER BIOMARKERS MARKET: DEGREE OF COMPETITION
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 38 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 12.5.5 COMPANY FOOTPRINT
      • 12.5.5.1 Overall company footprint
    • FIGURE 39 CANCER BIOMARKERS MARKET: OVERALL COMPANY FOOTPRINT
      • 12.5.5.2 Product footprint
    • TABLE 324 CANCER BIOMARKERS MARKET: PRODUCT FOOTPRINT
      • 12.5.5.3 Profiling technology footprint
    • TABLE 325 CANCER BIOMARKERS MARKET: PROFILING TECHNOLOGY FOOTPRINT
      • 12.5.5.4 Application footprint
    • TABLE 326 CANCER BIOMARKERS MARKET: APPLICATION FOOTPRINT
      • 12.5.5.5 Regional footprint
    • TABLE 327 CANCER BIOMARKERS MARKET: REGIONAL FOOTPRINT
  • 12.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES (2023)
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • FIGURE 40 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
    • 12.6.5 COMPETITIVE BENCHMARKING
    • TABLE 328 CANCER BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
    • TABLE 329 CANCER BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • 12.7 VALUATION AND FINANCIAL METRICS OF CANCER BIOMARKER VENDORS
    • FIGURE 41 EV/EBITDA OF KEY VENDORS
    • FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • 12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
    • FIGURE 43 PRODUCT/BRAND COMPARATIVE ANALYSIS
    • 12.8.1 F. HOFFMANN-LA ROCHE LTD.
    • 12.8.2 AGILENT TECHNOLOGIES, INC.
    • 12.8.3 QIAGEN
    • 12.8.4 ABBOTT
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 330 CANCER BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2024
    • 12.9.2 DEALS
    • TABLE 331 CANCER BIOMARKERS MARKET: DEALS, JANUARY 2021-MARCH 2024

13 COMPANY PROFILES

  • (Business overview, Products offered, Recent developments & MnM View)**
  • 13.1 KEY PLAYERS
    • 13.1.1 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 332 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
    • FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
    • TABLE 333 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED
    • TABLE 334 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 335 F. HOFFMANN-LA ROCHE LTD.: DEALS
    • 13.1.2 THERMO FISHER SCIENTIFIC INC.
    • TABLE 336 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
    • TABLE 337 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
    • TABLE 338 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 339 THERMO FISHER SCIENTIFIC INC.: DEALS
    • 13.1.3 QIAGEN
    • TABLE 340 QIAGEN: COMPANY OVERVIEW
    • FIGURE 46 QIAGEN: COMPANY SNAPSHOT (2023)
    • TABLE 341 QIAGEN: PRODUCTS & SERVICES OFFERED
    • TABLE 342 QIAGEN: PRODUCT LAUNCHES & APPROVALS
    • TABLE 343 QIAGEN: DEALS
    • 13.1.4 BIO-RAD LABORATORIES, INC.
    • TABLE 344 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 345 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
    • 13.1.5 ILLUMINA, INC.
    • TABLE 346 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 48 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 347 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED
    • TABLE 348 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 349 ILLUMINA, INC.: DEALS
    • 13.1.6 AGILENT TECHNOLOGIES, INC.
    • TABLE 350 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • FIGURE 49 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 351 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
    • TABLE 352 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 353 AGILENT TECHNOLOGIES, INC.: DEALS
    • 13.1.7 ABBOTT LABORATORIES
    • TABLE 354 ABBOTT: COMPANY OVERVIEW
    • FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2023)
    • TABLE 355 ABBOTT: PRODUCTS & SERVICES OFFERED
    • 13.1.8 BIOMERIEUX
    • TABLE 356 BIOMERIEUX: COMPANY OVERVIEW
    • FIGURE 51 BIOMERIEUX: COMPANY SNAPSHOT (2023)
    • TABLE 357 BIOMERIEUX: PRODUCTS & SERVICES OFFERED
    • 13.1.9 MERCK KGAA
    • TABLE 358 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 52 MERCK KGAA: COMPANY SNAPSHOT (2023)
    • TABLE 359 MERCK KGAA: PRODUCTS & SERVICES OFFERED
    • TABLE 360 MERCK KGAA: DEALS
    • TABLE 361 MERCK KGAA: OTHER DEVELOPMENTS
    • 13.1.10 BECTON, DICKINSON AND COMPANY
    • TABLE 362 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 53 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
    • TABLE 363 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED
  • *Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
  • 13.2 OTHER PLAYERS
    • 13.2.1 MYRIAD GENETICS, INC.
    • 13.2.2 SYSMEX CORPORATION
    • 13.2.3 HOLOGIC, INC.
    • 13.2.4 QUEST DIAGNOSTICS
    • 13.2.5 CENTOGENE N.V.
    • 13.2.6 BIOGENEX
    • TABLE 364 BIOGENEX: COMPANY OVERVIEW
    • 13.2.7 SIEMENS HEALTHINEERS
    • 13.2.8 EXACT SCIENCES
    • 13.2.9 R&D SYSTEMS, INC.
    • 13.2.10 BIOVISION INC.
    • 13.2.11 OLINK
    • 13.2.12 ASURAGEN, INC.
    • 13.2.13 MESO SCALE DIAGNOSTICS, LLC
    • 13.2.14 INVIVOSCRIBE, INC.
    • 13.2.15 INOVIQ LTD.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS